secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0000950170-24-073312
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna presents data update on KYV-101 CAR T therapy at EULAR symposium
------------------------------------------------------------------------

- CEO Peter Maag introduced symposium; external speakers presented long-term clinical experience with anti-CD19 CAR T in autoimmune diseases.
- KYV-101 data covered experience across multiple autoimmune diseases and sites, presented by James Chung, MD, PhD of Kyverna.
- Panel discussion featured academic and Kyverna experts on KYV-101's potential in rheumatologic autoimmune indications.
- No specific numerical efficacy or safety results were disclosed in the furnished presentation materials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000095017024073312/0000950170-24-073312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000095017024073312/kytx-20240614.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-073312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer